Channel Therapeutics CORP

Pelthos Therapeutics announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026.

Pelthos Therapeutics Inc. announced a change in its independent registered public accounting firm and detailed the separation terms for its former CFO.

Pelthos Therapeutics Inc. reported first quarter 2026 financial results, highlighting a 17% quarter-over-quarter increase in ZELSUVMI net product revenue and providing updates on its expanding sales force and strategic acquisitions.

Pelthos Therapeutics announced its CEO will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026.

Pelthos Therapeutics Inc. announced the appointment of John M. Gay as Chief Financial Officer, effective April 10, 2026, succeeding Francis Knuettel II.

Pelthos Therapeutics reports strong ZELSUVMI sales growth and strategic acquisitions, positioning for future revenue expansion.

Pelthos Therapeutics Inc. reported a net loss of $10.2 million for the first quarter of 2026, with revenues driven by its lead product, ZELSUVMI.

Pelthos Therapeutics Inc. reported its Q3 2025 financial results, marking its first product revenues following the commercial launch of ZELSUVMI, alongside significant merger and financing activities, but also disclosed substantial net losses and material weaknesses in internal controls.

Pelthos Therapeutics reports increased losses but secures $50.1 million in new capital and completes a transformative merger, shifting focus to commercializing FDA-approved Zelsuvmi.

Channel Therapeutics reports a net loss of $1.97 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also announcing a merger agreement with LNHC, Inc.

Chromocell Therapeutics reported a net loss of $6.0 million for the nine months ended September 30, 2024, while continuing to advance its pain treatment programs.

Chromocell Therapeutics reported a net loss of $4.3 million for the second quarter of 2024, alongside updates on its clinical programs and financial position.

Pelthos Therapeutics Inc. reports a net loss of $43.3 million for 2025, driven by commercialization efforts for ZELSUVMI and recent acquisitions of XEPI and XEGLYZE, while securing $30 million in new financing.

Channel Therapeutics Corporation files its 2024 10-K, detailing financial results and providing updates on its pain management therapeutic programs.

Chromocell Therapeutics Corporation's 2023 10-K filing highlights its focus on developing non-opioid pain treatments, including CC8464 for neuropathic pain and CT2000 for eye pain, while also expanding its pipeline through strategic licensing.

Director Ezra Friedberg of Pelthos Therapeutics Inc. reported the sale of 534 shares of common stock on July 2, 2026, for an aggregate price of $26.0303 per share, as part of a pre-arranged 10b5-1 plan.

Pelthos Therapeutics Director Matthew Pauls reported the sale of company common stock valued at over $1.8 million, executed under a pre-arranged trading plan.

Pelthos Therapeutics Director Peter Greenleaf reported a sale of common stock valued at approximately $18,500, executed under a Rule 10b5-1 trading plan.

Director Ezra M. Friedberg sold 283 shares of Pelthos Therapeutics Inc. to satisfy tax obligations related to RSU vesting.

Director Todd Davis purchased 35,948 shares of Pelthos Therapeutics common stock in open market transactions.

Pelthos Therapeutics Inc. reports changes in beneficial ownership for CFO Francis Knuettel II, including stock option acceleration and share sales upon his departure.

Pelthos Therapeutics Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and approve a critical waiver for its $18 million convertible note financing, which could lead to significant shareholder dilution.

Channel Therapeutics Corporation is set to merge with LNHC, Inc., a Ligand Pharmaceuticals subsidiary with an FDA-approved product, in a transaction that will rename the combined entity Pelthos Therapeutics Inc. and include a $50.1 million private investment.

Chromocell Therapeutics is seeking stockholder approval for several key proposals, including reincorporation in Nevada, an amendment to its equity incentive plan, and a waiver of the exchange cap for certain financings.

Chromocell Therapeutics aims to raise up to $30 million through a committed equity financing facility with Tikkun Capital, as detailed in their S-1 filing.

Chromocell Therapeutics is seeking to raise capital through an IPO to further the development of its pain management therapeutics, primarily focusing on its lead compound CC8464 for Erythromelalgia.

Chromocell Therapeutics updates its S-1 filing, detailing IPO share offerings, potential resale by stockholders, and progress in developing its pain therapeutic, CC8464.

Chromocell Therapeutics updates its S-1/A filing for an initial public offering, aiming to list on the NYSE American under the symbol CHRO.

Chromocell Therapeutics aims to raise capital for pain therapeutics development through an initial public offering.

Chromocell Therapeutics amends a senior secured convertible note and files a resale prospectus for existing stockholders in connection with its IPO.

Pelthos Therapeutics Inc. has secured a $9.0 million Senior Secured Convertible Note from Ligand Pharmaceuticals Incorporated, enhancing its financial position and granting Ligand significant royalty interests.

Pelthos Therapeutics Inc. has filed an amended Schedule 13D, detailing updated beneficial ownership stakes for Ezra Friedberg, Balmoral Financial Group LLC, and Key Recovery Group LLC following a reverse stock split, a merger, and a private investment in public equity (PIPE) financing.

Ligand Pharmaceuticals Incorporated has become a significant beneficial owner of Pelthos Therapeutics Inc., holding 49.9% of its common stock, following the completion of a merger and a private investment in public equity (PIPE) financing.

Ikarian Capital, LLC and Neil Shahrestani have reported a 7.7% beneficial ownership stake in Pelthos Therapeutics Inc. via a Schedule 13G filing.

Investment firm 3i, LP and affiliates report a 9.9% beneficial ownership stake in Pelthos Therapeutics Inc. via Schedule 13G amendment.

3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, updated their beneficial ownership in Pelthos Therapeutics Inc. to 9.99% of common stock.

Ikarian Capital, LLC and Neil Shahrestani have reported a 6.1% passive beneficial ownership stake in Pelthos Therapeutics Inc., holding 186,408 shares of common stock.

Murchinson Ltd. and CEO Marc Bistricer have jointly reported a 9.1% beneficial ownership stake in Pelthos Therapeutics Inc., totaling 280,000 shares.

AME Equities LLC and Ruth Friedman have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than 5% of Pelthos Therapeutics Inc. common stock.